1.	Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
2.	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: PETHEMA-LAM07, NCT01041040
3.	Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT) Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 21 and under Sponsor: Other Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
4.	Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes Phase: Phase IV Type: Treatment Status: Active Age: 10 to 90 Sponsor: Other Protocol IDs: MST/MDS-307PLAH-ASH, NCT01674985
5.	Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: BfArM 4022064, DKH 50-2728, UCHM-AML-BFM-2004, UCHM-BfArM 4022064, UCHM-DKH 50-2728, EU-20723, AML-BFM 2004, NCT00111345
6.	Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
7.	Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: IAPLSG2004, BT/PR4460/Med/14/531/2003, NCT00517712
8.	Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Phase: Phase III, Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: MT2006-13, 0607M89052, UMN-MT2006-13, NCT00630565
9.	Low-energy Laser Therapy for Prevention of Oral Mucositis in Children Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Active Age: 0 to 18 Sponsor: Other Protocol IDs: CHU-0060, NCT01007617
10.	Unrelated Double Umbilical Cord Blood Units Transplantation Phase: Phase III, Phase II Type: Treatment Status: Active Age: 1 to 50 Sponsor: Other Protocol IDs: HORCSCT-0902, NCT01015742
11.	Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS Phase: Phase III, Phase II Type: Treatment Status: Approved-not yet active Age: 16 to 80 Sponsor: Other Protocol IDs: CHG-DAC 001, SHDC12010202, NCT01417767
12.	Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2 Phase: Phase III Type: Treatment Status: Active Age: 18 and under Sponsor: Other Protocol IDs: P030441, AOM 03142, NCT00149162
13.	Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
14.	Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: AML SCT-BFM 2007, 2007-004517-34, NCT00606723
15.	Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0307, NCT00619879
16.	Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: NCI, Other Protocol IDs: AML08, 5R01CA138744, 1R01CA115422, NCT00703820
17.	A Study Comparing Single Versus Double Umbilical Cord Blood Transplantation in the Young With Acute Leukemia Remission Phase: Phase III Type: Health services research, Treatment Status: Active Age: Under 35 Sponsor: Other Protocol IDs: 2009-17, 2009-A00792-55, NCT01067300
18.	Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia Phase: Phase III Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: ICC APL STUDY 01, NCT01226303
19.	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
20.	Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: NCI-2011-02670, AAML1031, U10CA098543, COG-AAML1031, NCT01371981
21.	PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: PRO#1278: Flu-Bu-TBI, NCT01366612
22.	Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Phase: Phase III Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: 2011-0628, NCT01471444
23.	HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia Phase: Phase III Type: Treatment Status: Active Age: 7 to 60 Sponsor: Other Protocol IDs: MST-AML-307PLAH-ASH, NCT01484171
24.	Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: AML HIDAC, AIIMS, NCT01615757
25.	Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: Busulfan-2013, NCT01800643